权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Education Core)

2/2 药物开发和能力建设：UCR/CoH-CCC 合作伙伴关系（教育核心）

基本信息

批准号：
10249137
负责人：
Maurizio Pellecchia
金额：
$ 2.82万
依托单位：
UNIVERSITY OF CALIFORNIA RIVERSIDE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-02 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10249137
关键词：
African American American Antineoplastic Agents Applications Grants Award Basic Science Bioinformatics Biology California City of Hope Comprehensive Cancer Center Clinical Clinical Trials Collaborations Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility Data Drug Design Drug Targeting Eating Education Education and Outreach Educational Curriculum Engineering Ethics European Exposure to Faculty Funding Goals Health Sciences Hispanic Americans Hispanic-serving Institution Inequality Institution Investments Joints Laboratories Latino Master&apos s Degree Medical Students Mentorship Methods NCI Center for Cancer Research Participant Patients Persons Pharmaceutical Preparations Phase Phase I Clinical Trials Phase II Clinical Trials Physicians Precision Medicine Initiative Reporting Research Research Infrastructure Research Personnel Resources Rotation Running Scientist Societies Students System Testing Therapeutic Clinical Trial Training Training Programs Translating United States United States Food and Drug Administration United States National Institutes of Health Universities Visit anticancer research cancer health disparity career chimeric antigen receptor T cells clinical translation community clinic community partnership curriculum development disparity elimination diversity and equity diversity and inclusion drug development drug discovery drug repurposing education research education resources ethnic diversity experience first-in-human graduate student health disparity innovation manufacturing facility medical schools minority communities nanotherapy news next generation novel therapeutics outreach precision drugs precision medicine programs research and development screening social determinants stem cell therapy success summer research targeted agent undergraduate student virtual

项目摘要

Abstract: University of California at Riverside (UCR) is the newest medical school in the University of California system and a NIH-designated ISUPS institution. UCR's mandate is to serve SoCal's majority-minority communities and train the next generation of Latino/Hispanic-American and Black/African-American engineers, biologists, and physicians. City of Hope Comprehensive Cancer Center (CoH-CCC) is a Comprehensive Cancer Center whose 121 researchers have been awarded over $75M in NIH/NCI funding. CoH-CCC leads the world in academic drug discovery and has commercialized blockbusters drugs such as HumalinTM, HerceptinTM, and RituximabTM. CoH has world-class bioinformatics for drug design, extensive screening and synthetic capability, three onsite GMP-manufacturing facilities, and a robust clinical/translation Phase I program. Over the past 5 years 21 drugs have gone from R01 concept to first-in-man testing. The goal of the Collaborative Cancer Research Education Program (C-REP) is for UCR and CoH-CCC to develop the research experiences, curriculum, and outreach education resources necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. Aim 1: Research Experiences will provide tailored research experiences in cancer research and drug development. Aim 2: Curriculum Development will provide courses to introduce both UCR and CoH students and faculty to methods and innovation in drug development and the health science of disparities. Aim 3 Outreach Education and Resources will 1) expose early stage investigators to career opportunities drug development and clinical trials and 2) provide training and capacity building for fellows and faculty to translate their findings to drive drug discovery.

摘要：加州大学滨江分校（UCR）是加州大学系统中最新的医学院和NIH指定的IUPS机构。UCR的任务是为南加州的少数族裔社区服务并培养下一代拉丁裔/西班牙裔美国人和黑人/非洲裔美国人工程师，生物学家，和医生。City of Hope Comprehensive Cancer Center（CoH-CCC）是一家综合性癌症中心。其121名研究人员获得了超过7500万美元的NIH/NCI资助。CoH-CCC引领世界学术药物发现，并已商业化的重磅药物，如优泌林TM，赫赛汀TM， Rituximab TM. CoH拥有世界一流的药物设计生物信息学，广泛的筛选和合成能力，三个现场GMP生产设施和一个强大的临床/翻译I期计划。过去5 21年来，21种药物已经从R 01概念发展到首次人体试验。合作癌症研究教育计划（C-REP）的目标是UCR和CoH-CCC 开发必要的研究经验，课程和推广教育资源，以发展下一代的治疗学研究人员，反映了内陆南加州的种族多样性。目的 1：研究经验将提供量身定制的癌症研究和药物研究经验发展目标2：课程开发将提供课程，介绍UCR和CoH学生和教师的方法和创新的药物开发和健康科学的差距。目标3 外展教育和资源将1）使早期研究人员接触到职业机会，开发和临床试验，2）为研究员和教师提供培训和能力建设，他们的发现来推动药物发现。